IXICO plc Investor Meet Company presentation

TIDMIXI

IXICO plc

16 May 2023

IXICO plc

("IXICO" or the "Company")

Half-year results investor presentation via Investor Meet Company.

IXICO PLC is pleased to announce that Giulio Cerroni (CEO), Grant Nash (CFO) and Robin Wolz (CSO) will provide a live presentation relating to the half-year results of the Company via the Investor Meet Company platform on 23rd May 2023 at 4:30pm BST. The presentation is open to all existing and potential shareholders.

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via:

https://www.investormeetcompany.com/ixico-plc/register-investor .

Investors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.

For further information please contact:

 
 IXICO plc                                              +44 (0)20 3763 7499 
 Giulio Cerroni, Chief Executive 
  Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                      +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Michael F Johnson / Tamar Cranford-Smith 
  (Sales)

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough machine learning Ai data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASFFFMIEDSEDI

(END) Dow Jones Newswires

May 16, 2023 02:00 ET (06:00 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Mar 2024 to Apr 2024